Skip to content

CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016
39.10 +0.17 +0.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
81.12% -0.86pp
Institutions
612 +2
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund61.26%
Hedge Fund6.62%
VC/PE Fund6.05%
Public Company2.95%
Private Company1.95%
Government Pension Fund1.51%
Individual/Insider0.52%
Sovereign Wealth Fund0.30%
Family Office/Trust0.25%
Other18.58%

Top holders as of 2026-09-30

ARK Investment Management LLC 10.37% · 10.06M sh
BlackRock 8.56% · 8.30M sh
Capital Research 6.41% · 6.22M sh
Orbis Investment Management Limited 5.62% · 5.45M sh
State Street Global Advisors 5.15% · 4.99M sh
GSK Equity Investments, Limited 2.69% · 2.61M sh
Geode Capital Management, LLC 2.59% · 2.51M sh
T. Rowe Price Group, Inc. 2.25% · 2.18M sh
SR One Capital Management, LP 2.10% · 2.04M sh
Two Sigma Investments, LP 2.05% · 1.99M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 34 buys · 13 sells

NameRoleStake
Samarth Kulkarni Chairperson & CEO 0.32%
James Kasinger General Counsel 0.10%
Douglas Treco Lead Independent Director 0.02%
Naimish Patel Chief Medical Officer 0.02%
Ali Behbahani Independent Director 0.02%
Simeon George Independent Director 0.02%
Raju Prasad Officer 0.02%
John Greene Independent Director 0.01%
Briggs Duncan W. Morrison Independent Director 0.01%
Katherine High Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-05 Raju Prasad Officer Intent to Sell (Form 144) -79,393 $49.88
2026-11-03 Sivakesava Sakhamuri Chief Technology Officer Other Derivative Acquisition +40,000 --
2026-11-03 Sivakesava Sakhamuri Chief Technology Officer Other Derivative Acquisition +90,000 $51.78
2026-10-25 Samarth Kulkarni Chairperson & CEO Other Derivative Acquisition +28,750 --
2026-10-25 Samarth Kulkarni Chairperson & CEO Other Derivative Acquisition +57,500 $49.01
2026-10-25 Naimish Patel Chief Medical Officer Other Derivative Acquisition +12,000 --
2026-10-25 Naimish Patel Chief Medical Officer Other Derivative Acquisition +24,000 $49.01
2026-10-25 James Kasinger General Counsel Other Derivative Acquisition +9,000 --
2026-10-25 James Kasinger General Counsel Other Derivative Acquisition +18,000 $49.01
2026-10-25 Andrew Silver CFO, Principal Financial Officer & Principal Accounting Officer Other Derivative Acquisition +9,000 --
2026-10-25 Andrew Silver CFO, Principal Financial Officer & Principal Accounting Officer Other Derivative Acquisition +18,000 $49.01
2026-10-18 Samarth Kulkarni Chairperson & CEO Derivative Exercise and Sale -47,837 $49.78
2026-10-18 Andrew Silver CFO, Principal Financial Officer & Principal Accounting Officer Other Derivative Acquisition +25,000 --
2026-10-18 Andrew Silver CFO, Principal Financial Officer & Principal Accounting Officer Initial Statement of Beneficial 0 --
2026-10-15 Samarth Kulkarni Chairperson & CEO Derivative Exercise and Retained +52,163 --
2026-10-13 Simeon George Independent Director Derivative Exercise and Sale -14,514 $14.00–49.63
2026-10-13 Simeon George Independent Director Derivative Exercise and Retained +15,486 $14.00
2026-10-13 Samarth Kulkarni Chairperson & CEO Derivative Exercise and Sale -4,098 $49.26
2026-10-13 James Kasinger General Counsel Derivative Exercise and Sale -1,040 $49.26
2026-10-12 Samarth Kulkarni Chairperson & CEO Derivative Exercise and Retained +4,235 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.

CRISPR Therapeutics discussion 0 comments

Add a comment